Abstract Number: 0990 • ACR Convergence 2024
Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…Abstract Number: 1042 • ACR Convergence 2024
Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
Background/Purpose: Patient-reported outcome measures (PROMs) are essential tools for prioritizing patient-centric care and enhancing health system-performance measurement in rheumatology. Effective use of PROMs collected in…Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…Abstract Number: 1338 • ACR Convergence 2024
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed…Abstract Number: 1354 • ACR Convergence 2024
The Association of Genetic Variation in PTPN22 and Rheumatoid Arthritis Disease Activity
Background/Purpose: PTPN22 R620W is a common genetic variation that is a known risk factor for the development of autoimmune disease, including rheumatoid arthritis (RA). This…Abstract Number: 1370 • ACR Convergence 2024
Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
Background/Purpose: To descriptively compare treatment patterns, persistence and effectiveness of upadacitinib (UPA), other JAK inhibitors (JAKi) and tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis…Abstract Number: 1387 • ACR Convergence 2024
Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study
Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…Abstract Number: 1405 • ACR Convergence 2024
Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis
Background/Purpose: Musculoskeletal conditions, including osteoarthritis (OA), osteoporosis (OP), rheumatoid arthritis (RA), and chronic pain, significantly burden individuals' health and well-being. These conditions often lead to…Abstract Number: 1682 • ACR Convergence 2024
Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor
Background/Purpose: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are under investigation in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib (LY3871801;…Abstract Number: 1846 • ACR Convergence 2024
Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis
Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…Abstract Number: 1905 • ACR Convergence 2024
Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Background/Purpose: Several peripheral biomarkers for RA-associated interstitial lung disease (RA-ILD) have been evaluated to enhance early RA-ILD identification. The MUC5B rs35705950 promoter variant, matrix metalloproteinase-7…Abstract Number: 2121 • ACR Convergence 2024
Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
Background/Purpose: Spontaneous lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…Abstract Number: 2217 • ACR Convergence 2024
A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…Abstract Number: 2234 • ACR Convergence 2024
Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
Background/Purpose: RA-associated interstitial lung disease (ILD) is a heterogeneous disease with a chronic course and potential for flares. Serum biomarkers are needed to identify those…Abstract Number: 2251 • ACR Convergence 2024
Stress-Related Neural Activity Measured with FDG-PET/CT Is Associated with Articular Disease Activity, Systemic Inflammation, and Treatment-associated Change in Arterial Inflammation in Rheumatoid Arthritis
Background/Purpose: The amygdala, a limbic structure of the brain’s salience network, links chronic external stressors with downstream effects on the HPA axis and hematopoietic tissues…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 188
- Next Page »